Invasive Breast Carcinoma
📧 Sign up to get email alerts when something new happens for Invasive Breast Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-28Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial evaluating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; currently active-not-recruiting.
-
CLINICAL_TRIALS trial_result · 2026-07-31Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial exploring pembrolizumab as adjuvant therapy for triple-negative breast cancer is actively not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-07-02Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 clinical trial update for pembrolizumab as adjuvant therapy in triple-negative breast cancer, status ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS trial_result · 2026-07-01Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial evaluating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer is ongoing with active status.
-
CLINICAL_TRIALS trial_result · 2026-06-25Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial evaluating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; ongoing ACTIVE_NOT_RECRUITING trial …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial investigating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; currently active but not recruiti…
-
CLINICAL_TRIALS trial_result · 2024-02-13Clinical Trial Update: Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative [Phase 2]
Phase 2 trial evaluating liposomal doxorubicin, bevacizumab, and everolimus in locally advanced triple-negative breast cancer predicted inse…
-
CLINICAL_TRIALS trial_result · 2023-06-27Clinical Trial Update: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer [Phase 3]
Phase 3 trial evaluating tamoxifen citrate, letrozole, anastrozole, or exemestane with or without chemotherapy in invasive breast cancer (Rx…
-
CLINICAL_TRIALS trial_result · 2022-12-06Clinical Trial Update: Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer [Phase 1]
Phase 1 trial evaluating bexarotene for preventing breast cancer in high-risk individuals; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer [Phase 2]
Phase 2 trial update investigating talazoparib before standard therapy in invasive, BRCA-mutated breast cancer shows completed status with p…
-
CLINICAL_TRIALS trial_result · 2019-09-20Clinical Trial Update: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer [Phase 2]
Phase 2 trial updates trametinib combined with an AKT inhibitor (GSK2141795) in metastatic triple-negative breast cancer; study completed wi…